Generalized Anxiety Disorder (GAD)

The short version

●Generalized anxiety disorder (GAD) is a DSM-5-TR anxiety disorder defined by excessive, difficult-to-control worry about multiple events or activities, occurring more days than not for at least six months, accompanied by physical and cognitive symptoms.
●This page is a GAD-specific clinical deep-dive; the broader /ketamine-for-anxiety route covers anxiety as a whole. GAD is the chronic, pervasive-worry anxiety disorder — distinct from the discrete attacks of panic disorder or the social-evaluation focus of social anxiety disorder.
●The GAD-7 is the standard 7-item screening and severity instrument (Spitzer and colleagues): scores of 5, 10, and 15 mark mild, moderate, and severe anxiety; a cutoff of 10 is the usual threshold for likely GAD.
●First-line pharmacotherapy is SSRIs and SNRIs (escitalopram, sertraline, paroxetine, duloxetine, venlafaxine); buspirone is a non-sedating, non-dependence-forming first-line alternative; pregabalin is first-line in some guidelines (Europe).
●Cognitive-behavioral therapy is the first-line psychotherapy, with strong evidence; it targets the intolerance of uncertainty and maladaptive beliefs about worry that maintain GAD. Combination with medication is appropriate for moderate-to-severe presentations.
●Benzodiazepines provide rapid relief but are not first-line for chronic GAD because of dependence, cognitive effects, and the chronic course of the disorder; their role is limited and short-term.
●Ketamine is not first-line for GAD; its evidence base in anxiety is growing (Mills 2025 BJPsych showed measurable anxiety reduction), and it is reasonably considered for treatment-resistant GAD, especially with comorbid treatment-resistant depression.

Clinical definition

DSM-5-TR generalized anxiety disorder requires: (A) excessive anxiety and worry occurring more days than not for at least 6 months, about a number of events or activities; (B) the worry is difficult to control; (C) the anxiety and worry are associated with at least three of six symptoms (restlessness or feeling keyed up, being easily fatigued, difficulty concentrating, irritability, muscle tension, sleep disturbance) — only one symptom is required in children; (D) the symptoms cause clinically significant distress or impairment; (E) not attributable to a substance or medical condition; (F) not better explained by another mental disorder (e.g., the worry is not confined to panic, social evaluation, contamination, etc.). ICD-11 (6B00) frames GAD around either general apprehension ("free-floating anxiety") or excessive worry across multiple domains, with similar associated symptoms. GAD is among the most common anxiety disorders in primary care, has a typically chronic and fluctuating course, peaks in prevalence in middle age, and is highly comorbid with major depression — so much so that the two are sometimes hard to separate cross-sectionally. The cognitive core, emphasized in modern models, is intolerance of uncertainty and positive/negative beliefs about the function of worry, which is what cognitive-behavioral therapy specifically addresses. Standardized screening with the GAD-7 (a validated 7-item self-report scale; Spitzer and colleagues, 2006) is now routine in primary care and useful for both detection and tracking treatment response.

How it differs from related conditions

vs. Panic disorder

Panic disorder centers on recurrent discrete panic attacks and fear of further attacks; GAD is sustained, pervasive worry without the defining acute attacks. GAD patients may feel chronically "keyed up" but do not have the abrupt surges that define panic. The two frequently co-occur and respond to overlapping medications but different psychotherapy targets.

vs. Social anxiety disorder

Social anxiety worry is specifically about scrutiny and negative evaluation in social or performance situations; GAD worry spans many unrelated domains (work, finances, health, family, minor matters). If the worry is confined to social situations, social anxiety disorder is the diagnosis. Both can co-occur (covered at /conditions/social-anxiety-disorder).

vs. Illness anxiety disorder

Illness anxiety disorder worry is exclusively about having or getting a serious illness; GAD includes health as just one of many worry domains. If health dominates to the exclusion of other worries, illness anxiety disorder fits better (covered at /conditions/health-anxiety).

vs. Major depressive disorder (MDD)

GAD and MDD overlap heavily and frequently co-occur; sustained worry and rumination can look similar. The distinguishing features of MDD are low mood and anhedonia as the core; in GAD the core is apprehensive worry and physical tension with mood relatively preserved. When both are fully present, both are diagnosed — and the comorbid depression is what may justify ketamine.

First-line treatments

SSRIs (escitalopram, sertraline, paroxetine)

First-line pharmacotherapy with broad regulatory approval and strong evidence in GAD. Escitalopram, paroxetine, and sertraline are well-supported. Start low to limit early activation, titrate to therapeutic dose; onset of anxiolytic effect is 2-6 weeks with full benefit by 12 weeks. Continue at least 6-12 months after response given the chronic, relapse-prone course.

SNRIs (duloxetine, venlafaxine XR)

First-line alongside SSRIs, with FDA approval in GAD. Useful particularly with comorbid depression or chronic pain. Venlafaxine XR start-low (37.5 mg) to limit activation; blood-pressure monitoring at higher doses. Duloxetine is well-tolerated and has additional benefit in coexisting neuropathic pain. The Strawn and colleagues review summarizes the comparative pharmacotherapy evidence.

Buspirone

A non-sedating, non-dependence-forming 5-HT1A partial agonist with first-line evidence in GAD. No abuse potential and no withdrawal syndrome, making it attractive for patients with substance-use history or those wanting to avoid benzodiazepines. Onset is gradual (2-4 weeks); requires consistent dosing (typically two to three times daily). Less effective in patients recently treated with benzodiazepines.

Cognitive-behavioral therapy (CBT)

First-line psychotherapy with robust evidence in GAD. Modern GAD-CBT targets intolerance of uncertainty, positive and negative beliefs about worry, and the avoidance and reassurance behaviors that maintain it, using worry-exposure, cognitive restructuring, and relaxation/applied-relaxation components. Effect sizes are large; gains are durable and complementary to medication.

Pregabalin

A first-line option in several European guidelines for GAD, with rapid onset (within the first week) and a mechanism (alpha-2-delta calcium channel modulation) distinct from antidepressants. Sedation, dizziness, and weight gain are common; misuse potential is lower than benzodiazepines but not zero. A useful choice when antidepressants fail or rapid effect is desired under appropriate monitoring.

Mindfulness-based and structured movement interventions

Mindfulness-based stress reduction and related programs reduce GAD symptoms in randomized trials. A head-to-head trial (Simon and colleagues, JAMA Psychiatry) found yoga and CBT both outperformed stress-education for GAD, with CBT showing the more durable effect — supporting structured mind-body interventions as reasonable adjuncts or alternatives, particularly for patients who prefer non-pharmacologic options.

Benzodiazepines (limited, short-term role)

Effective for rapid symptom relief but explicitly NOT first-line for chronic GAD because of dependence, tolerance, cognitive and psychomotor effects, and the disorder's long-term course. Appropriate uses are narrow: a short-term bridge while an SSRI/SNRI takes effect, or brief use during an acute crisis. Long-term daily benzodiazepine treatment of GAD is discouraged in current guidelines.

When standard treatments fail

For treatment-resistant GAD after a first adequate SSRI trial: switch to a second SSRI or to an SNRI (duloxetine or venlafaxine XR) at full dose for an adequate duration → consider buspirone or pregabalin (different mechanisms) as monotherapy or augmentation → ensure an adequate course of GAD-specific CBT has been delivered (generic supportive counseling is often insufficient — the worry-exposure and intolerance-of-uncertainty work is what drives response) → consider augmentation with low-dose atypical antipsychotic (e.g., quetiapine) in refractory cases, weighing metabolic burden → consider hydroxyzine or, in narrow short-term circumstances, a benzodiazepine bridge. A recurring reason for apparent treatment resistance is undertreated comorbid major depression; when both are present, treating the depression adequately frequently improves the anxiety, and a treatment-resistant depressive component is what opens the door to rapid-acting options such as ketamine.

Where ketamine fits

Ketamine is not first-line for generalized anxiety disorder. The GAD-specific trial evidence is limited, but the broader anxiolytic signal is growing — the Mills 2025 BJPsych analysis from the Ketamine for Adult Depression trial found measurable reductions in anxiety symptoms alongside the antidepressant effect across a diagnostically heterogeneous cohort, supporting an anxiolytic mechanism relevant to anxiety-spectrum presentations. Clinically, ketamine becomes a reasonable consideration for GAD in two situations: treatment-resistant GAD that has not responded to adequate trials of multiple SSRIs/SNRIs (and ideally buspirone or pregabalin) plus GAD-specific CBT, and — more commonly and more strongly supported — GAD with a co-occurring treatment-resistant major depressive disorder, where ketamine targets the depression and the broader anxiolytic effect benefits the GAD secondarily. Because some GAD patients are prone to anticipatory and somatic anxiety, the dissociative phenomenology of a session benefits from explicit preparation and, where needed, dose adjustment.

Where this fits with Tovani

Tovani treats GAD when standard treatments have been adequately tried — typically at least two SSRI/SNRI trials at therapeutic dose plus a course of GAD-specific CBT, often with a trial of buspirone or pregabalin as well. Eligibility screening uses the GAD-7 to quantify severity and track change, and captures prior treatment history. In practice, many patients presenting with treatment-resistant anxiety have a substantial comorbid depressive component; that depression is usually the primary indication, with the broader anxiolytic effect of ketamine benefiting the GAD. Patients with prominent anticipatory or somatic anxiety receive extra preparation about the dissociative experience of a session, and the physician adjusts dose for those more prone to anxiety during treatment.

Check eligibility The science behind ketamine

Frequently asked

How is GAD different from just being a worrier?

GAD is defined by excessive, hard-to-control worry across multiple areas of life, occurring more days than not for at least six months, plus physical symptoms like restlessness, fatigue, muscle tension, irritability, and sleep problems, and it causes real distress or impairment. Ordinary worry is proportionate, controllable, and does not dominate your days or impair functioning. The GAD-7 questionnaire is a quick, validated way to gauge whether worry has crossed into clinical territory.

What is the GAD-7 and what score means I have anxiety?

The GAD-7 is a 7-item self-report scale that measures anxiety symptom severity over the past two weeks. Scores of 5, 10, and 15 correspond to mild, moderate, and severe anxiety, and a score of 10 or above is the usual threshold for likely generalized anxiety disorder warranting clinical assessment. It is also useful for tracking whether treatment is working over time.

What is the best first treatment for GAD?

First-line options are SSRIs (escitalopram, sertraline, paroxetine) or SNRIs (duloxetine, venlafaxine), buspirone (a non-sedating, non-addictive alternative), and cognitive-behavioral therapy. Pregabalin is first-line in some guidelines. For moderate-to-severe GAD, combining medication with CBT works well. Benzodiazepines are not first-line for chronic GAD because of dependence and the long-term course of the disorder.

Can ketamine help my GAD?

It is not a first-line treatment. The anxiety-specific evidence is growing — a 2025 analysis found ketamine reduced anxiety symptoms alongside its antidepressant effect — but there is no large GAD-specific trial. Ketamine is more reasonably considered for treatment-resistant GAD after adequate trials of SSRIs/SNRIs and CBT, and especially when GAD coexists with treatment-resistant depression, in which case it primarily treats the depression and the anxiety benefits secondarily.

Is GAD the same thing as anxiety in general?

No — "anxiety" is an umbrella term, and GAD is one specific disorder within it. Our broader page on ketamine for anxiety covers the whole spectrum, while this page focuses on GAD specifically: the chronic, pervasive-worry form. Other anxiety disorders include panic disorder (discrete attacks), social anxiety disorder (fear of judgment), and illness anxiety disorder (fear of being seriously ill) — each diagnosed and treated somewhat differently.

References

Strawn JR et al. 2018, Expert Opinion on Pharmacotherapy — Review of pharmacotherapy for generalized anxiety disorder in adults and adolescents — establishes SSRIs and SNRIs as first-line, with buspirone, pregabalin, and second-line and augmentation options for treatment-resistant GAD. (PMID 30056792)
Spitzer RL et al. 2006, Archives of Internal Medicine — Validation of the GAD-7, a brief 7-item measure for assessing generalized anxiety disorder — the standard screening and severity-tracking instrument used in primary care, with a cutoff of 10 for likely GAD. (PMID 16717171)
Simon NM et al. 2021, JAMA Psychiatry — Randomized trial of yoga versus cognitive behavioral therapy versus stress education for generalized anxiety disorder — both yoga and CBT outperformed stress education, with CBT showing the more durable effect. (PMID 32805013)
Mills NT et al. 2025, British Journal of Psychiatry — Ketamine for Adult Depression study analysis of anxiety outcomes — measurable anxiety reduction alongside antidepressant effect in a diagnostically heterogeneous cohort, supporting an anxiolytic mechanism relevant to treatment-resistant GAD with comorbid depression. (PMID 39763417)

Last reviewed by Dr. Ben Soffer, DO on May 27, 2026. This page is educational and not a substitute for clinical evaluation. A physician determines whether ketamine therapy is appropriate for your specific situation.